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Molecular design of hybrid tumour necrosis factor alpha with
polyethylene glycol increases its anti-tumour potency
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Sm_nmary This study was conducted to increase the anti-tumour potency and reduce the toxic side-effects of
tumour necrosis factor alpha (TNF-a). Natural human TNF-a was chemically conjugated with monomethoxy
polyethylene glycol (PEG) using succinimidyl coupling of lysine amino groups of TNF-a. The number-average
molecular weight of PEG-modified TNF-a (PEG-TNF-() increased with an increase in the reaction time and
the initial molar ratio of PEG relative to TNF-a. The resulting modified TNF-a was separated into fractions
of various molecular weights. The specific activity of separated PEG-TNF-xs relative to that of native TNF-a
gradually decreased with an increase in the degree of PEG modification, but the plasma half-life was
drastically increased with the increase in mokcular weight of modified TNF-a. PEG-TNF-ms, in which 29%
and 56% of lysine residues were coupled to PEG, had anti-tumour activity approximately 4 and 100 times
greater than unmodified TNF-a in the murine Meth-A fibrosarcoma model. Extensive PEG modification did
not increase its in vivo activity. A high dose of unmodified TNF-a induced toxic side-effects, but these were not
observed with the modified TNF-zs. Optimal PEG modification of TNF-a markedly increased its
bioavailability and may facilitate its potential anti-tumour therapeutic use.
Keywords: molecular design; chemical modification; polyethylene glycol. tumour necrosis factor-a, anti-tumour
potency
Tumour necrosis factor alpha (TNF-m), a physiologically
important cytokine produced by activated macrophages,
plays multiple roles as a mediator of inflammation and the
immune response (Gamble et al., 1985; Cavender et al.,
1987). TNF-a has potentially synergistic anti-tumour effects,
such as direct cytotoxicity against tumour cells, indirect
cytotoxicity by activating a host immune anti-tumour res-
ponse and selective impairment of the microcirculation in the
capillaries of the tumour tissue (Nobuhara et al., 1987; Debs
et al., 1990). Thus, TNF-z was expected to be a valuable
anti-tumour therapeutic agent. However, TNF-a is rapidly
cleared from the blood circulation, and excessively high doses
of TNF-x are required to produce significant anti-tumour
clinical effects (Moritz et al., 1989; Noguchi et al., 1991).
TNF-x has been found to have unexpected toxic side-effects,
typified by pyrexia, tissue inflammation and injury and a
lethal endotoxic shock-like syndrome (Blick et al., 1987;
Kimura et al., 1987; Debs et al., 1990). Nevertheless, high
doses of TNF-a cause complete regression of various trans-
planted solid tumours in mice (Carswell et al., 1975; Manda
et al., 1987; Tamura et al., 1989). This suggests that an
increase in the bioavailability of TNF-a may increase its
clinical potency, thus facilitating more effective use of TNF-x
as an anti-tumour drug.
Clinical applications of proteins such as superoxide dis-
mutase (SOD) and adenosine deaminase (ADA) are limited
because of their rapid clearance from the blood as a result of
glomerular filtration, proteolysis, hepatic uptake and
immunogenicity (Pyatak et al., 1980; Hershfield et al., 1991).
In recent years, chemical modification of proteins with poly-
ethylene glycol (PEG) and albumin has been found to over-
come these drawbacks effectively (Kamisaki et al., 1981;
Abuchowski et al., 1984; Poznansky, 1986). For instance,
PEG-modified proteins have been proved to have increased
plasma half-lives and stability and reduced immunogenicity
in vivo. These effects are attnrbuted to the increased molecular
weight and steric hindrance that result from PEG attached to
proteins. However, the clinical application of such modified
proteins is limited as yet. This is because of the conflicting
effects of chemical modification of proteins: the transport
from blood to target tissues of modified proteins is limited by
their high molecular weight, and receptor binding is sterically
inhibited, resulting in loss of bioactivity. Nevertheless, an
optimal modification could achieve well-balanced tissue
transport, receptor binding and plasma clearance. For the
molecular design of modified proteins applicable to clinical
use, the discovery of the optimisation of modification condi-
tions, determined by the steric hindrance and molecular
weight, should be a primary concern.
In this study, we attempted to optimise modification of
TNF-x with PEG to increase further its anti-tumour potency.
Synthetic PEG-TNF-a was separated into various molecular
weight fractions, that is with various degrees of PEG
modification, to study the relationship between steric hind-
rance, molecular weight and anti-tumour activity. This in-
formation will enable us to design modified proteins suitable
for therapeutic use.
Materials and methods
Materials
Natural human TNF-x was kindly supplied by Hayashibara
Biological Laboratories (Okayama, Japan). N-succinimidyl
succinate monomethoxy polyethylene glycol (SS-PEG; MW =
5000) was obtained from Sigma (St Louis, MO, USA).
Carrier-free ['2"I]sodium iodide was purchased from Nordion
International (Ontario, Canada). Other reagents and solvents
were of analytical grade.
Aninals and cells
Female Balb/c mice (5 weeks old) were purchased from SLC
(Hamamatsu, Japan). L-M cells and Meth-A fibrosarcoma
cells were generously provided by Mochida Pharmaceutical
(Tokyo, Japan). L-M cells were serially subcultured in
Eagle's minimum essential medium containing 10% fetal calf
serum (FCS; Filtron, Brooklyn, NY, USA). Meth-A fibrosar-
coma cells were maintained intraperitoneally by serial pas-
sages in female Balb/c mice.
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Conjugation ofPEG to T.NF-
A typical procedure for preparation of PEG-modified TNF-x
(PEG-TNF-m) is as follows. TNF-x in 0.2 M phosphate
buffer. pH 7.2. was allowed to react with a 60-fold molar
excess of SS-PEG at room temperature for 10 min. The
reaction was stopped by addition of a 5-fold molar excess of
e-amino caproic acid over the SS-PEG. The resulting PEG-
TNF-x was purified and separated into fractions of various
molecular weights by gel filtration chromatography (GFC;
TSKgel G3000SWXL, Tosoh. Tokyo. Japan; GFC buffer =
0.2 M phosphate buffer, pH 7.2). The number-average
molecular weight (M.) of separated PEG-TNF-oxs was
estimated by GFC and the degree of PEG modification was
calculated from Mn. The protein concentration of native
TNF-a and PEG-TNF-oxs was determined from the absor-
bance at 280 nm, which for PEG is zero. The specific
activities of native TNF-x and PEG-TNF-xs were measured
by cytotoxic activity against L-M cells (L-M cytotoxicity
assay) according to the method described by Yamazaki et al.
(1986), and were expressed in terms of the Japan reference
unit (JRU), defined previously (Yamazaki et al., 1986).
Pharmacokinetics ofPEG-TNF-x
Native TNF-x and PEG-TNF-ms were labelled with '"I by
the lactoperoxidase method (Marchalonis, 1969), yielding
['2IrTNF-( and ['II1PEG-TNF-.s with specific radioactivities
of 23.8 mCi mg-' protein. The biological activity of the
['"IrTNF-( and ['UIPEG-TNF-.s was indistinguishable from
that of native TNF-4 and PEG-TNF-zs. Meth-A fibro-
sarcoma cells (4 x 10) were implanted intradermally in the
abdomen of 5-week-old female Balb/c mice. Seven days later,
the pharmacokinetics of native TNF-x and PEG-TNF-as was
studied at a dose of 20 ng of protein per mouse. After
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Figure I Preparation of PEG-modified TNF-a. The number-
average molecular weight (M.) was measured by GFC analysis
before separation into various M. fractions of PEG-modified
TNF-axs. (a) Time-dependent effect of the number-average
molecular weight (MJ) of PEG-modified TNF-z. The initial
molar ratio of PEG relative to TNF-a was 10. (b) Effect of the
initial molar ratio of PEG relative to TNF-z on the M. of
PEG-modified TNF-z. The reaction time was 30min.
intravenous administration, blood was collected from the tail
vein at various time points and the radioactivity was
measured. The plasma half-lives of native TNF-a and PEG-
TNF-xs were evaluated by curve fitting with the non-linear
least-squares method (Yamaoka et al.. 1981).
Evaluation ofin vivo anti-tumour effects
Meth-A fibrosarcoma cells were maintained and implanted as
described above. On day 7. native TNF-a and PEG-TNF-os
were given i.v. as a single injection. Drug efficacy against
Meth-A was expressed as mean tumour volume, scores of
tumour haemorrhagic necrosis and lifespan. Tumour volume
was calculated from the formula described by Haranaka et
al. (1984). Tumour haemorrhagic necrosis was scored accord-
ing to the method described by Carswell et al. (1975) 24 h
after injection.
Statistical analysis
Statistical evaluations of tumour volume and tumour hae-
morrhagic necrotic score were analysed by the Student t-test.
For survival of mice. Wilcoxon rank-sum analysis was used.
Results
Preparation and characterisation ofPEG-TNF-a
Natural human TNF-c was coupled to PEG via an amide
bond between a lysine amino residue of TNF-a and a ter-
minal succinimidyl succinate group of PEG. The degree of
PEG modification depended on the coupling reaction time as
well as the initial molar ratio of PEG relative to TNF-x
(Figure 1). A longer reaction time and higher concentration
of PEG relative to TNF-x yielded higher molecular weight
PEG-TNF-(. The resulting PEG-TNF-x was separated into
various Mn fractions by GFC to study in detail the relation-
ship between steric hindrance, molecular weight and bio-
activity. Table I shows the Mn. degree of PEG modification
and specific activity of separated PEG-TNF-as, which was
prepared with a reaction time of 10 mmn and an initial molar
ratio of PEG relative to native TNF-a of 10. An increase in
the degree of PEG modification was accompanied with a
decrease in its bioactivity. Extensive PEG modification
resulted in the complete loss of bioactivity in vitro. The
separated PEG-TNF-(xs, in which 29%, 56% and 71% of the
lysine amino groups of TNF-hc were coupled to PEG. were
termed LPEG-TNF-x, MPEG-TNF-cx and HPEG-TNF-z
respectively. The major product of this coupling condition
was MPEG-TNF-(c.
Pharmacokinetics ofPEG-T.NF-as
The pharmacokinetics of native TNF-a and PEG-TNF-oxs
after i.v. administration to the Meth-A solid tumour-bearing
mice was studied at 20 ng of protein per mouse. lodination
did not lead to a reduction in the biological activity of native
TNF-( and PEG-TNF-(xs measured by the L-M cytotoxicity
assay. The serum concentration profiles of native TNF-a and
PEG-TNF-ars showed biexponential elimination (Figure 2).
At 3 h after injection, most of the native TNF-a was cleared
from the circulation. The plasma half-life of native TNF--x
was 3.2 mm in good agreement with that reported previously
(Moritz et al.. 1989; Noguchi et al.. 1991). By contrast,
PEG-TNF-os showed a markedly increased plasma level. The
GFC analysis of collected blood at 3 h after injection
indicated that PEG-TNF-is did not bind to TNF-soluble
receptors. The plasma half-lives were 14-fold higher with
LPEG-TNF-a (45 mmn), 37-fold higher with MPEG-TNF-x
(117 min) and 43-fold higher with HPEG-TNF-x (136mn)
than with native TNF-a. The area under the PEG-TNF-os
serum concentration curve (AUC) and residence time were
much higher than for native TNF-x.
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Table I Characterisation of PEG-modified TNF-xs
Nwnber average Degree of Specific activity Remaining Yield
molecular weighf modfication (%)b (x 104 JRU/mg TNFf activity (%) (%)
148 000 100 2.19 3.00 1.0 23.2
122000 71 30.8 + 10.3 14.1 36.4 HPEG-TNF-e
108 000 56 114 20.6 52.3 24.6 MPEG-TNF-a
84 000 29 163 ± 2.40 74.5 10.2 LPEG-TNF-x
58000 0 218 4.59 100.0 5.6 Native TNF-a
aDetermined by GFC (protein standard). bCakculated from number-average molecular weight. 'Assessed by
growth inhibition of L-M tumour cell assay.
Anti-tunour effects ofPEG-TNF-os
The anti-tumour effects of a single i.v. injection of native
TNF-41 and PEG-TNF-xs on the Meth-A solid tumour-bear-
ing mice was studied. Native TNF-x slightly inhibited
tumour growth (Figure 3), and the necrotic scores were
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Fipe 2 Pharmacokinetics of native TNF-x (-), and PEG-
TNF-as (0, LPEG-TNF-a; A, MPEG-TNF-a A, HPEG-TNF-
a) in tumour-bearing mice after intravenous injection. Mice were
used in groups of four. Each value is mean ± s.e.
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dose-dependently higher at 24 h after i.v. injection on day 7
(Figure 4). However, all native TNF-a-treated mice died
during the experimental period (Table II). One of the seven
mice administered native TNF-a at a dose of 10 000 JRU
died within 24 h after injection, and the remaining sLx mice
developed piloerection, tissue inflammation and transient
decrease in the body weight during the experimental period
(data not shown). At a dose of 10 000JRU of native TNF-x,
sudden death and these side-effects are always observed, as
they were in this study. Thus 10 000JRU of native TNF--a
was the maximal achievable therapeutic dose. By contrast,
the anti-tumour response of LPEG-TNF-x and MPEG-TNF-
ax was significantly increased compared with native TNF-a
(Figures 3 and 4). This was especially true for MPEG-TNF-
cx, in which relatively high bioactivity, approximately 100
times higher than native TNF-a, was maintained even at a
relatively high Mn. As shown in Figures 3 and 4, MPEG-
TNF-a at a dose of 200 JRU had an anti-tumour effect
superior to that of native TNF-x at a dose of 10 000 JRU.
Complete regression was obtained in two of seven mice at a
small dose of 200 JRU (Table II). During the experimental
period, all doses of MPEG-TNF-a were well tolerated and
body weight reduction was not observed (data not shown).
However, HPEG-TNF-m, which had a higher M., higher
degree of PEG modification and longer plasma half-life than
LPEG-TNF-x and MPEG-TNF-a, had anti-tumour effects
similar to those of native TNF-x (Figures 3 and 4 and Table
II). As expected, PEG (10 .Lg per mouse) had no anti-tumour
effect (Figures 3 and 4 and Table II).
LPEG-TNF-a
HPEG-TNF-a
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Days after tumor inoculation
Fugwe 3 Anti-tumour effects of native TNF-x and PEG-TNF-as on Meth-A solid tumours. Mice were used in groups of seven.
Each value is mean ± s.e. Statistical significanc compared with salne control: *P<0.001.
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Figre 4 Tumour necrotic effects of native TNF-c and PEG-
TNF-as on Meth-A solid tumours. Mice were used in groups of
seven. Each value is mean ± s.e. Statistical significance compared
with saline control: *P<0.001. Significant difference from the
group treated with 1OOOOJRU of native TNF-a: **P<0.05.
Table II Anti-tumour effect of native TNF-a and PEG-modified
TNF-as on survival days after Meth-A tumour inoculation
Single i.v.
injection dose
(JRU per Survival timea Complete
Run mouse) (dta!s) regressionb
Saline 0 30.6 2.6 0/7
PEG 0 30.1 2.1 0 7
Native TNF-a 1000 33.3 ± 3.0 0 7
2000 35.0 2.2 0'7
5000 39.9 3.0 07
10000 39.9±6.0 07
LPEG-TNF-a 500 35.1 ± 2.0 0 7
1000 36.9 1.4 0`7
2000 42.7±3.2* 07
5000 52.1 ±8.5** 1 7
MPEG-TNFl- 50 41.9 2.1** O7
100 44.9 3.0* 0 7
200 61.7 10.2** 2,7
500 55.9 ± 7.8** 1,7
1000 61.6± 10.1** 2, 7
HPEG-TNF-a 1000 33.9 ± 1.14 0 7
'Days after tumour inoculation (n = 7, mean ± s.e.). bComplete
regression was defined when tumour was not regrown for more than
150 days. Statistical significance compared with saline control:
*P<0.02: **P<0.005.
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Human cytokines such as TNF-a, interleukin 2 (IL-2) and
interferon-y (IFN-y) have been produced on a large scale by
using natural and recombinant DNA expression in cultured
cells, and have recently been introduced as candidates for
new drugs (Rosenberg et alt, 1984; Aggarwal et al., 1985;
Arakawa et al., 1985). The high doses of cytokines required
for significant clinical effects, because of their short plasma
half-lives, often induce toxic side-effects (Rosenberg et al.,
1987; Wadler, 1992). In recent years, PEG modification of
cytokines has been found to increase their plasma stability as
a result of the increase in molecular weight and steric hind-
rance effects (Katre et al., 1987; Kita et al., 1990). However,
as pointed out in the introduction, chemical modification
reduces the specific activity and tissue transport (Goodson
and Katre, 1990). Few detailed studies have been performed
with the aim of overcoming these drawbacks of chemical
modification. After due consideration of these problems. we
performed chemical modification of TNF-a with PEG.
The PEG modification most likely occurred at some of the
lysine c-amino residues. The molecular weight and degree of
PEG modification were found to be controlled by the
amount of the activated PEG relative to TNF-a and the
coupling reaction time (Figure 1). Most modified proteins in
previous studies had an extremely broad polydispersion and
did not separate into various M. fractions. It was difficult to
determine the relationship between steric hindrance, molec-
ular weight and bioactivity by using these broad size range
samples, so the synthetic PEG-TNF-xs were separated into
various Mn fractions. The specific activity of PEG-TNF-a
relative to that of native TNF-a gradually decreased with an
increase in the degree of PEG modification (Table I). Exten-
sive PEG modification resulted in the complete loss of bio-
activity in vitro. By contrast, PEG-modified SOD and ADA
maintained relatively high specific activities even at an exten-
sive degree of PEG modification (Pyatak et al., 1980;
Hershfield et al., 1991). These findings may be due to the fact
that the substrates of SOD and ADA are very small
molecules, so the steric hindrance caused by PEG chains
attached to proteins may not affect the enzymic activity. In
addition, the active site of the proteins may be small enough
to be invulnerable to chemical modification. These findings
strongly suggest that PEG chains sterically inhibit
TNF-receptor binding and that some lysine amino residues
of TNF-a play an important role in bioactivities. These
results are partly supported by the fact that Lys-l1 fulfils a
structural role (Ostade et al.. 1991). In addition, chemical
modification of IFN-y with PEG inhibited receptor binding
(Kita et al., 1990). To determine the mechanisms of the loss
of in vitro TNF-a bioactivity after chemical modification,
more detailed studies such as receptor binding assays are
necessary. As is well known, lysine modification with PEG is
random and difficult to control. Therefore, PEG modification
at a site that does not inactivate the protein would be
preferred. Recently to overcome effectively this drawback of
chemical modification, Goodson and Katre (1990) reported
that site-directed PEG modification of interleukin 2 sustained
full bioactivity relative to native interleukin 2. This site-
directed PEG modification technique may enable us to
prepare PEG-TNF-x in which high specific activity is main-
tained even at a high molecular weight.
Native TNF-a was rapidly cleared from blood, and the
plasma half-life was 3.5 min (Figure 2). The rapid clearance
of native TNF-a in mice as a result of glomerular filtration in
the kidney, proteolysis and hepatic uptake was predicted.
Attachment of PEG to TNF-x markedly decreased its plasma
clearance. The explanation for the decrease in the plasma
clearance of PEG-TNF-x may be the shielding of the proteo-
lytic sites in TNF-(x by PEG chains. PEG-modified proteins
have been shown to be more resistant to proteolysis than the
corresponding unmodified protein (Lisi et al., 1982). In addi-
tion, the renal clearance of PEG-TNF-( is speculated to be
prevented by increasing the molecular weight through cova-
lent attachment of PEG. In general, the clearance by the
kidney is slower for a larger protein (Maack et al., 1979).
Thus, the glomerular filtration of PEG-modified IL-2 de-
creased with an increase in its molecular weight (Knauf et al.,
1988). An increase in the extent of PEG modification caused
a progressive increase in the plasma half-life. Therefore, if the
size of the modified protein, which is determined by the steric
factors as well as the molecular weight, is the rate-deter-
mining step in the in vivo clearance mechanism, the molecular
weight of the PEG attached to TNF-xmay be also important
in influencing the pharmacokinetics of PEG-modified TNFY-.
The systemic administration of TNF-x in high doses often
induces toxic side-effects (Blick et al., 1987,Kimura et al.,
1987). Therefore, cancer therapy with TNF-a has been limit-
ed to intratumoral administrations (Pfreundschuh et al.,
1989). In the Meth-A murine solid tumour model, LPEG-
TNF-a and MPEG-TNF-x had a higher anti-tumour activity
than native TNF-a (Figures 3 and 4). In particular MPEG-
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TNF-x was 100-fold more potent than natie TNF-a, and
induced complete regreson in two of the sev mice at a
dose of only 20 JRU (Tabk I). The remaining five mice
had a markedly prolongd survival time. At the dose of
1000JRU of MPEG-TNF-a, which is five times higher than
the dose at which the maximal anti-tumour effect was
obsrved, no TNF-a-mediated toxicity was detected (data not
shown). MPEG-TNF-x enable us to reduc the therpeutic
dose ofTNF-a, resuling in d s side-effects. We believe
that MPEG-TNF-a is a prosng potential anti-tumour
agent in systemic therapy. By contrast, HPEG-TNF-a, which
has a higher M. than MPEG-TNF-a, did not show an in-
ased anti-tumour response compared with native TNF-a
(Figures 3 and 4 and Table Ii). It is of interest to consider
the diffence in in vivo activity of PEG-TNF-cs. Tlhis
difference may be partly accounted for by plasma learance
and tissue tansport. LPEG-TNF-a might be easy to trans-
port to tumour tissue, but was rapidly clared because of its
smallr molecular size than MPEG-TNF-a, resulting in a
decrease in the bioavailability. On the other hand, it might be
harder to transport HPEG-TNF-a to tumour tissue than
MPEG-TNF-a because ofits larger molecular size. Therefore
we believe that MPEG-TNF-a among the versions of PEG-
TNF-as prepared is the best miodification produet For PEG-
modified TNF-a to become appicble to cinical use, the
relationship between tissue transport and plasma clarance
should be carefuly considered in order to prepare PEG-
modified TNF-z with more potent anti-tumour activity.
Until now, many biologially active proteins have been
covalently modified with water-soluble polymers for clinical
use, but clincal applcation has been limited as yet More
detai studies, such as on tumour transport and plasma
clarnce relationships, or steric and bioactivity
relationships, are nesary to improve the design of the
modified protein incuding TNF-i At least, we found that
modified protein which has higher bioactivity in vivo can be
obtained by separating the modified protein into various M.
fiactions. In conclusion, our studies demonstrate that opti-
mal modification of TNF-a with PEG markedly increases its
anti-tumour poteny and also reduces its toxic side-effects.
MPEG-TNF-a has high in anti-tumour activity and was
no less efficacious in a mouse tumour model than other
anti-tumour drugs, including other PEG-modified cytokines
previously reported. MPEG-TNF-x may be a useful deriva-
tive as a potential anti-tumour therapeutic agent.
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